The role of caspase and calpain in neuronal apoptosis and pathogenesis of Huntington disease

Neuroscience Bulletin

Volumn 21, Issue 3, 2005, Pages 224-229

  Wang, Yan ^a   Gu, Zhen Lun ^a   Qin, Zheng Hong ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Apoptosis; Calpain; Caspase; Huntingtin; Huntington disease; Neurodegenerative disorders

Indexed keywords

CALPAIN; CALPASTATIN; CASPASE; CYSTAMINE; LEUPEPTIN; MINOCYCLINE; PD 150606; PROTEASOME; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; CELL NUCLEUS INCLUSION BODY; CELLULAR DISTRIBUTION; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME SUBSTRATE; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PATHOGENESIS; REVIEW; UNSPECIFIED SIDE EFFECT; WILD TYPE;

EID: 35948942793     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature, 2000, 407(6805):802-809.
2. Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci, 2004, 13(8):1979-1987.
3. Rossi F, Cattaneo E. Neural stem cell therapy for neurological diseases: dreams and reality. Nat Rev Neurosci, 2002, 3(5):401-409.
4. Yamashima T. Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates. Prog Neurobiol, 2000, 62(3):273-295.
5. Cheng EHY, David G, Kirsch, et al. Conversion of Bcl-2 to a bax-like death effector by caspases. Science, 1997, 278(5345):1966-1968.
6. Deveraux QL, Schendel SL, Reed JC. Antiapoptotic proteins: the bcl-2 and inhibitor of apoptosis protein families. Cardiol Clin, 2001, 19(1):57-74.
7. Leavitt BR, Guttman JA, Hodgson JG, et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet, 2001, 68(2):313-324.
8. Rigamonti D, Sipione S, Goffredo D, et al. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem, 2001, 276(18):14545-14548.
9. Hermel E, Gafni J, Propp SS, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ, 2004, 11(4):424-438.
10. Gafni J, Ellerby LM. Calpain activation in Huntington's disease. J Neurosci, 2002, 22(12):4842-4849.
11. Gafni JG, Hermel E, Young JE, et al. Inhibition of calpain cleavage of huntingtin reduces toxicity, accumulation of calpain/caspase fragments in the nucleus. J Biol Chem, 2004, 279(19):20211-20220.
12. Wellington CL, Ellerby LM, Gutekunst CA, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci, 2002, 22(18):7862-7872.
13. Sawa A, Tomoda T, Bae BI. Mechanisms of neuronal cell death in Huntington's disease. Cytogenet Genome Res, 2003, 100(1-4):287-295.
14. Michalik A, Van Broeckhoven C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet, 2003, 12(90002):R173-186.
15. Kim YJ, Yi Y, Sapp E, et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA, 2001, 98(22):12784-12789.
16. Kiechle T, Dedeoglu A, Kubilus J, et al. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Med, 2002, 1(3):183-195.
17. Zhou H, Cao FL, Wang ZS, et al. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol, 2003, 163(1):109-118.
18. Qin ZH, Wang Y, Kegel KB, et al. Autophagy regulates processing of amino terminal htuntingtin fragments. Hum Mol Genet, 2003, 12(24):3231-3244.
19. Qin ZH, Wang Y, Sapp E, et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci, 2004, 24(1):269-281.
20. Leegwater-Kim J, Cha JHJ. The Paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration. NeuroRx, 2004, 1(1):128-138.
21. Bonelli RM, Kapfhammer HP. Why minocycline is helpful in Huntington's disease. J Psychopharmacol, 2003, 17(4):461.
22. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington's disease, with administration of the transglutaminase inhibitor cystamine. Nat Med, 2002, 8(2):143-149.
23. Lesort M, Lee M, Tucholski J, et al. Cystamine inhibits caspase activity: Implications for the treatment of polyglutamine disorders. J Biol Chem, 2003, 278(6):3825-3830.
24. Kieran D, GreensmithL. Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration. Neuroscience, 2004, 125(2):427-439.